Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03335670 · ClinicalTrials.gov registry record · Early Phase 1
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
A Early Phase 1 study of Neuroendocrine Tumors, sponsored by Yusuf Menda.
- Active
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03335670 is a Early Phase 1 study of Neuroendocrine Tumors that is active but no longer recruiting, run by Yusuf Menda. The registered enrollment target is 30 participants, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03335670, a Early Phase 1 study of Neuroendocrine Tumors, is active but no longer recruiting, sponsored by Yusuf Menda.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate how Gallium-68 Pentixafor is distributed in neuroendocrine tumor patients and if that distribution is consistent through repeated scans. This is an RDRC study - as such, the images obtained for this study cannot be used clinically or shared with treating oncologists.
Conditions Studied
Interventions
- DRUG [68Ga]Pentixafor
Study Locations (1)
Iowa
- Holden Comprehensive Cancer Center - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-11-03 |
| Est. Completion | 2030-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03335670
The ClinicalTrials.gov registry entry for NCT03335670 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (83% lower). The listed sponsor is Yusuf Menda, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 1 intervention - of which [68Ga]Pentixafor is the first listed.
NCT03335670 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT03335670 about?
NCT03335670 is a clinical study titled "Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors". This study will evaluate how Gallium-68 Pentixafor is distributed in neuroendocrine tumor patients and if that distribution is consistent through repeated scans. This is an RDRC study - as such, the images obtained for this study cannot be used clinically or shared with treating oncologists.
What is the current status of trial NCT03335670?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2017-11-03. Estimated completion is 2030-06-30.
What conditions does trial NCT03335670 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors.
What interventions are being tested in trial NCT03335670?
The interventions under investigation include: [68Ga]Pentixafor (DRUG).
Who is sponsoring clinical trial NCT03335670?
This trial is sponsored by Yusuf Menda, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03335670 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
ACTIVE NOT RECRUITING · Early Phase 1
-
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
COMPLETED · Early Phase 1
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.